Figure 1.

Rapa inhibits body weight loss and improves MPTP-induced behavioral deficits in mice.

(A) Timeline of the experimental procedure. Mice were randomly divided into four groups and administered MPTP (25 mg/kg/day), Rapa (5 mg/kg/day) or RSL3 (25 mg/kg/day). (B) Effect of MPTP, Rapa, or RSL3 on body weight of mice. Pole-climbing (C) and traction (D) tests were used to assess motor function of mice. The data presented are from all animals and the samples were performed in triplicate. Data are expressed as the mean ± SEM (n = 8–10 per group). *P < 0.05 (one-way analysis of variance followed by Tukey’s post hoc test). MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Rapa: rapamycin; RSL3: methyl (1S,3R)-2-(2-chloroacetyl)-1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahyyridoindole-3-carboxylate.